Chemical formula: C₁₁H₁₆N₄O₄ Molecular mass: 268.269 g/mol PubChem compound: 71384
Dexrazoxane has two major mechanisms of action, chelation of iron and inhibition of topoisomerase II. It is not known to what extent each of these mechanisms contributes to the preventive effect on tissue destruction following anthracycline extravasation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V03AF02 | Dexrazoxane | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SAVENE Powder and solvent for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Dexrazoxane is an active ingredient of these brands:
Brazil (BR)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Ecuador (EC)
Estonia (EE)
Finland (FI)
France (FR)
Hong Kong (HK)
Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
Poland (PL)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
